Clarifying the role of flumonertinib rechallenge in EGFR-mutated non-small cell lung cancer Authors: Haoyu Wang, Chenyue Zhang, Shanshan Du, Haiyong Wang Published: 2026 We thank Li and colleagues for their interest in our recently published study and for their thoughtful comments regarding the role of flumonertinib rechallenge in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who have progressed on prior third-generation EGFR tyrosine kinase inhibitors (TKIs). We appreciate the opportunity to further clarify several methodological aspects of our work. As noted by Li et al. (1), identifying effective salvage treatment strategies after resistance to third-generation EGFR-TKIs remains an important clinical challenge. First, regarding the concern about potential selection bias and immortal time bias in the comparison across treatment lines, we acknowledge that retrospective real-world analyses are inherently susceptible to such limitations. In our study, the comparison between earlier and later lines of flumonertinib treatment was intended primarily as an exploratory analysis rather than a causal inference regarding treatment efficacy. In the present study, overall survival (OS) was defined as the time from the initiation of furmonertinib treatment to death. We acknowledge that, at the study design stage, OS was initially defined from the time of pathological diagnosis. Analyses based on this original definition did not demonstrate statistically significant differences among subgroups. Therefore, redefining OS from the initiation of furmonertinib treatment was considered more clinically relevant in the context of our study. Future prospective studies are warranted to further explore and validate these findings. Second, we agree that the relatively small sample size limits the statistical robustness of subgroup analyses. Given the limited number of patients who received flumonertinib after prior third-generation EGFR-TKI failure in real-world clinical practice, our analyses were intended to provide preliminary observations and generate hypotheses for future research, thereby providing exploratory insights. Furthermore, before the initiation of our study, several real-world investigations focusing on EGFR-TKI resistance had been reported. Compared with these studies, our sample size was relatively substantial. Third, Li et al. highlighted the limited molecular characterization in our cohort. We agree that understanding the molecular mechanisms of resistance is crucial in evaluating the potential role of EGFR-TKI rechallenge. However, as this was a retrospective real-world study, repeat molecular testing was not available for all patients due to practical constraints commonly encountered in clinical practice, including limited tissue availability, patient condition, and economic considerations. In addition, the relationship between furmonertinib and genetic mutations was not the main focus of our study. Future studies integrating comprehensive genomic profiling will be important to define better the subset of patients who may benefit from this strategy. Finally, given the retrospective design of this study, safety data collection was inevitably incomplete. However, it is important to emphasize that furmonertinib, as an oral targeted agent, has demonstrated a favorable safety profile. In our study, no apparent cases of interstitial lung disease (ILD) were observed in the 160 mg group. Moreover, its tolerability has been consistently supported by multiple real-world studies and clinical trials, even at higher doses. Future prospective studies with standardized safety monitoring will help to evaluate the tolerability of this treatment strategy further. In summary, we appreciate the constructive comments raised by Li and colleagues. While our study has inherent limitations related to its retrospective design and relatively small sample size, it provides preliminary real-world evidence in a clinical setting where effective treatment options remain limited. Further prospective investigations incorporating comprehensive molecular characterization are warranted to better clarify the potential role of flumonertinib rechallenge in patients with EGFR-mutated non-small cell lung cancer. Supplementary The article’s supplementary files as